Xceleron scientific advisory board expanded
Xceleron announced that it has brought in two new members to expand its scientific advisory board (SAB) under the chairmanship of Professor Malcolm Rowland. The board's role is to advise the company on further developing its core drug development technologies. Joining Professor Malcolm Rowland on the SAB will be pharmaceutical industry experts Dr Richard Jones and Dr Roy Bullingham.
Dr Jones is currently senior vice-president of experimental medicine and clinical and regulatory affairs at Aspreva Pharmaceuticals in Canada, prior to which he was Medical Director at Syngenta Biopharma in Switzerland. Dr Jones, who holds a doctorate in medicine from Oxford University, has also held senior management roles in drug development at Hoffman La Roche and Johnson & Johnson.
Dr Bullingham was most recently President and CEO of Daiichi Medical Research Inc following VP roles at Pharmacia and Syntex running global pharmacology and global research respectively. A graduate in organic chemistry from the University of Cambridge with an MD from London University, Dr Bullingham has published over 100 papers in clinical research and pharmacology across a wide range of therapeutic areas.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
